Document is current
Any future updates will be listed below
-
Authors
Martins, Cláudia
Mitchell, Michael J.
Peer, Dan
Perrie, Yvonne
Siegwart, Daniel J.
Alonso, María José
Aparicio-Blanco, Juan
- License Information
-
More Information
Article History
Accepted: 17 December 2025
First Online: 30 January 2026
Declarations
:
: Not applicable.
: Not applicable.
: All authors read and approved the final manuscript.
: M.J.M., D.J.S. and M.J.A. are named on patents describing the use of nanoparticles and nanoparticle compositions for nucleic acid delivery that are discussed in this perspective article. M.J.M. is a Scientific Advisor to and holds equity in Capstan Therapeutics. D.P. receives licensing fees (to patents on which he was an inventor) from, invested in, consults (or on scientific advisory boards or boards of directors) for, lectured (and received a fee), or conducts sponsored research at Tel Aviv University for the following entities: ART Biosciences, BioNtech SE, Earli Inc., Kernal Biologics, LAND Therapeutics, Merck, Newphase Ltd., NeoVac Ltd., RiboX Therapeutics, Roche, SirTLabs Corporation, Teva Pharmaceuticals Inc. D.J.S. discloses financial interests in ReCode Therapeutics, Signify Bio, Jumble Therapeutics, and Pegasus Bio. M.J.A conducts sponsored research in this field for Eli Lilly, and is also the founder and shareholder of LiberaBio. All other authors have no competing interests to declare.
Free to read: This content has been made available to all.
